Biotechnology

Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies

HOUSTON and SINGAPORE, July 12, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outcomes, andThe University of Texas MD Anderson Cancer Ce...

2021-07-12 17:00 809

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-07-12 08:12 2391

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

HANGZHOU, China and SAN FRANCISCO, July 12, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage, fast-growing biopharmaceutical company focusing on discovering and developing innovative therapies to treat chronic, metabolic and immunological diseases, announced today the...

2021-07-12 08:00 734

Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US

SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase...

2021-07-11 21:03 18328

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 - Ortho is ...

2021-07-10 03:33 29077

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile * ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South Ko...

2021-07-09 21:00 2000

Sequanta and Mission Bio announce strategic partnership

SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...

2021-07-09 15:44 727

Vaniam Group LLC announces European and International expansion with addition of new global agency, Vaniam Group Global Ltd

Dr. Louise Verrall appointed to lead Vaniam Group Global Ltd as Head of Europe & International CHICAGO, July 9, 2021 /PRNewswire/ -- Vaniam Group LLC today announced the establishment of Vaniam Group Global Ltd, expanding the company's strategic healthcare communications network footprint intoEu...

2021-07-09 06:50 1150

Yushangmei seeks to establish partnership with a new target company

GUANGZHOU, China, July 8, 2021 /PRNewswire/ -- Guangzhou Yushangmei Health Management Co., Ltd. announced the termination of the partnership with the company headquartered inNevada, USA. Meanwhile, Yushangmei has sought to establish partnership with a new target company, specific details will be ...

2021-07-08 19:29 1178

Aleph Farms Completes $105 Million Series B Funding Round

REHOVOT, Israel, July 8, 2021 /PRNewswire/ -- Aleph Farms , the cultivated meat company growing steaks directly from non-genetically modified animal cells, has announced the completion of a$105 million Series B funding round. The funding round was led by the Growth F...

2021-07-08 12:04 1290

BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer

SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...

2021-07-08 12:01 1395

Just 5 minutes: Game-changing PCR to complete nucleic acid amplification, Si-Gene Biotech help out against COVID 19

SHANGHAI, July 8, 2021 /PRNewswire/ -- As is known, nucleic acid detection is currently the "golden standard" of coronavirus detection and has the high sensitivity and specificity characteristics in early diagnosis. The most common method for detecting novel coronavirus-specific nucleic acid sequ...

2021-07-08 11:28 915

CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021

* AYVAKIT has demonstrated significant anti-tumor activity in Chinese patients with PDGFRA D842V mutant gastrointestinal stromal tumor (GIST), and has also shown potential for the treatment of fourth-line GIST * AYVAKIT had a generally well-tolerated safety profile in Chinese patients with GI...

2021-07-08 08:05 1461

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

* STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). * APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major co...

2021-07-07 06:34 905

LBB Specialties Enters Agreement with Leading Innovative Actives Manufacturer GREAF

NORWALK, Conn., July 7, 2021 /PRNewswire/ -- LBB Specialties (LBBS), a leader in North American specialty chemicals and ingredients distribution, announced it has entered a contractual agreement withGREAF, the global supplier of responsibly sourced, plant-derived novel active ingredients. The agr...

2021-07-07 01:45 947

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

PROVIDENCE, R.I., July 7, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce that Dr.Amy Rosenberg is leaving the FDA's Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenber...

2021-07-07 01:43 955

Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...

2021-07-06 21:06 17184

Bon Natural Life Limited Announces Land Acquisition to Construct Its Third Production Facility

XIAN, China, July 6, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health and personal care industries, today announced that they have received the certificate of a land use right for the future si...

2021-07-06 21:00 2383

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...

2021-07-06 18:00 16150

Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market

* Seegene announces partnership with Bio-Rad for the development and commercialization of infectious disease molecular diagnostic products * Diagnostic tests designed for the pandemic and the post-pandemic era with high multiplex technology * A significant step forward for Seegene in expandi...

2021-07-06 18:00 797
123456 ... 220